First-ever multi-drug Ebola trial launched in the Democratic Republic of Congo
A new trial has begun in the Democratic Republic of Congo, aiming to collect robust data on the safety and efficacy of investigational Ebola therapeutics.
Browsing: Clinical Trial
Gastroenteritis in children unscathed by treatment with probiotics
Concurrent major US and Canadian clinical trials prove probiotics to be ineffective in combatting gastroenteritis in children.
Novel antibiotic effective in the treatment of uncomplicated gonorrhea in Phase II trial
A Phase II, muti-center, randomized, open-label trial has reported that a novel oral antibiotic, zoliflodacin, is effective in the treatment of uncomplicated urogenital gonorrhea.
Shorter treatment duration a possibility for pulmonary TB
New data analysis of three clinical trials has suggested that a precision medicine approach could allow some pulmonary TB patients to have significantly shorter treatment periods.
Investigational antibiotic effective against drug-resistant UTIs in Phase II trial
A Phase II trial has demonstrated that a new investigational antibiotic, cefiderocol, is as effective as the current standard-of-care for treating complicated UTIs caused by multi-drug resistant bacteria.
FDA approves Xofluza™, the first single-dose oral medicine for influenza
Roche has announced the FDA approval of Xofluza™, the first and only single-dose oral medicine approved to treat flu.
The RESTORE-1 trial, results and real world repercussions – an interview with Keith Kaye
In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
Paratek’s antibiotic Nuzyra™ (omadacycline) gains FDA approval
The US FDA has approved Paratek Pharmaceuticals’ antibiotic Nuzyra™ (omadacycline) for the treatments of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Phase III trial suggests meropenem–vaborbactam a valuable option for CRE infection
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.
Merck’s ZERBAXA® meets primary endpoint in Phase III bacterial pneumonia study
Merck’s antibiotic ZERBAXA® (ceftolozane and tazobactam) has met its primary endpoint of non-inferiority compared with meropenem in a Phase III trial of patients with hospital-acquired and ventilator-associated bacterial pneumonia.
